Rare Daily Staff
The international venture capital firm 4BIO Capital said it has completed the first close of its second venture fund, 4BIO Ventures II with more than $50 million of capital committed from family offices and institutional investors.
The Group is targeting $150 million for the final close by the second half of 2020. The fund expects to invest in eight to 12 private companies developing advanced therapies, such as cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome—in areas of high unmet need.
4BIO said it is seeking to fund early-stage companies with the goal of ensuring sustainable access to potentially curative therapies for all patients. The fund will be focused on advanced therapies without geographic restrictions.
Since 2010 the Group and its founders have participated in 29 biotech investments across the advanced therapies sector, and 4BIO’s investment strategy has been validated by a number of recent exits including Orchard Therapeutics, Seres Therapeutics, and RetroSense Therapeutics, which was acquired by Allergan in 2016.
“We have presided over the significant growth and validation of the sector and supported the success of some of the sector’s most prominent companies, said Dmitry Kuzmin, managing partner of 4BIO Capital. “These funds will allow us to continue this success and support the field at this highly exciting time as it seeks to go beyond rare disease and address mainstream diseases such as diabetes, rheumatoid arthritis and Parkinson’s disease.”
Photo: Dmitry Kuzmin, managing partner of 4BIO Capital